01:17 , Feb 16, 2019 |  BC Extra  |  Company News

Emerging company roundup: Passage, IFM, Grey Wolf, Culture

In a week that had a pair of innovative Chinese companies raise early venture rounds and a Bay Area company debut its digital biomanufacturing platform, the biggest series A round went to Philadelphia gene therapy...
00:17 , Feb 16, 2019 |  BioCentury  |  Finance

Andera looks early for cancer immunotherapy

Andera Partners changed gears with an early investment in preclinical company Grey Wolf Therapeutics to diversify its cancer immunotherapy portfolio. Along with Canaan Partners, Andera backed a £10 million ($12.9 million) series A for Grey...
18:23 , Feb 15, 2019 |  BC Week In Review  |  Financial News

Andera, Canaan lead Grey Wolf £10M A round

Cancer immunotherapy company Grey Wolf Therapeutics closed the second tranche of its total £10 million ($12.9 million) series A round to fund development of its immuno-oncology therapies to increase tumor visibility. The round was led...
18:23 , Feb 15, 2019 |  BC Week In Review  |  Company News

Axovant spins out small molecule team to form CNS-focused newco

Following its pivot to gene therapy, Axovant Sciences Ltd. (NASDAQ:AXON) has spun out its small molecule team into Arvelle Therapeutics GmbH (Basel, Switzerland). The newco has raised more than $100 million and in-licensed exclusive European...
23:28 , Feb 14, 2019 |  BC Extra  |  Company News

Axovant spins out small molecule team to form CNS-focused newco

Following its pivot to gene therapy, Axovant Sciences Ltd. (NASDAQ:AXON) has spun out its small molecule team into Arvelle Therapeutics GmbH (Basel, Switzerland). The newco has raised more than $100 million and in-licensed exclusive European...
06:05 , Feb 11, 2019 |  BC Extra  |  Financial News

Andera, Canaan lead Grey Wolf £10M A round

Cancer immunotherapy company Grey Wolf Therapeutics closed the second tranche of its total £10 million ($12.9 million) series A round to fund development of its immuno-oncology therapies to increase tumor visibility. The round was led...
21:35 , Jan 11, 2019 |  BioCentury  |  Emerging Company Profile

Artios: Probing DNA Damage

With programs in-licensed from Cancer Research UK and Masaryk University, Artios Pharma Ltd. thinks it has next-generation DNA damage response programs that could improve upon PARP inhibitors -- and the funds to take them to...
18:03 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Gene therapy play LogicBio proposes IPO

Gene therapy company LogicBio Therapeutics Inc. (Cambridge, Mass.) proposed to raise up to $86 million in an IPO on NASDAQ underwritten by Jefferies, Barclays, William Blair and Chardan. LogicBio is developing gene therapies to address...
21:33 , Sep 26, 2018 |  BC Extra  |  Financial News

Gene therapy play LogicBio proposes IPO

Gene therapy company LogicBio Therapeutics Inc. (Cambridge, Mass.) proposed to raise up to $86 million in an IPO on NASDAQ underwritten by Jefferies, Barclays, William Blair and Chardan. LogicBio is developing gene therapies to address...
21:40 , Sep 25, 2018 |  BC Extra  |  Company News

Management tracks: Curis, Gemphire

Cancer company Curis Inc. (NASDAQ:CRIS) named COO James Dentzer president and CEO and appointed him as a board member. He replaces Ali Fattaey, who is departing. Curis had promoted Dentzer to COO this year. Cardiometabolic...